Plus Therapeutics to Present ReSPECT™-GBM Clinical Trial Data at the 2021 SNO Annual Meeting
Plus Therapeutics (Nasdaq: PSTV) announced it will present interim data from its ReSPECT™ Phase 1 clinical trial of Rhenium-186 NanoLiposome (186RNL) for recurrent glioblastoma at the Society for Neuro-Oncology Annual Meeting, scheduled for November 19, 2021. The presentation will cover the safety and feasibility of this innovative treatment. Dr. Andrew Brenner, the principal investigator, will lead the session, highlighting potential advancements in oncology therapeutics aimed at improving patient outcomes.
- Presentation of interim data on Rhenium-186 NanoLiposome indicates progress in clinical trials.
- Potential to improve treatment outcomes for patients with recurrent glioblastoma.
- No specific financial data or results disclosed for the ongoing trial.
- Risks regarding the early-stage product development and funding needs remain.
AUSTIN, Texas, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a U.S. clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present interim data on Rhenium-186 NanoLiposome (186RNL) from its ReSPECT™ Phase 1 clinical trial in recurrent glioblastoma (GBM) at the 2021 Society for Neuro-Oncology (SNO) Annual Meeting and Education Day being held November 18-21, 2021 in Boston, Massachusetts.
Details of the abstract and poster session are as follows:
| Title | Safety and Feasibility of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma: the ReSPECT™ Phase 1 Trial |
| Date | November 19, 2021 at 7:30 – 9:30 p.m. ET |
| Location | Exhibit Hall D, Hynes Convention Center |
| Presenter | Andrew J. Brenner, M.D., Ph.D., Associate Professor of Medicine, Neurology, and Neurosurgery at The University of Texas Health Science Center at San Antonio and principal investigator of the ReSPECT™ clinical trial |
Accepted abstracts will be made available on Thursday, November 11, 2021 at academic.oup.com/neuro-oncology/issue/22/Supplement_2.
A copy of the poster will be made available under the Presentations tab of the Investors section of the Company’s website at the time of the presentation at https://ir.plustherapeutics.com.
About Plus Therapeutics, Inc.
Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company’s drug development is a unique nanotechnology platform designed to formulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at PlusTherapeutics.com and ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “will,” “believe,” “plan,” “can,” “enable,” “design,” “intend,” “potential,” “expect,” “estimate,” “project,” “prospect,” “target,” “focus,” “anticipate,” “could,” “should,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the design and potential of the Plus Therapeutics portfolio to reformulate, deliver and commercialize multiple novel, proprietary drugs targeting rare cancers and other diseases and to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs; the potential of the Company’s in-licensed portfolio of investigational drugs; the Company’s intent to advance its CNS oncology portfolio through the clinical development process; the ability of RNL to safely, effectively and conveniently deliver a very high dose of radiation directly into the brain tumor; anticipated benefits of strategic collaborations and license agreements, intellectual property, FDA approval process and government regulation; and the Company’s anticipated milestones and events, including with respect to additional sites, enrollment, pivotal trial planning, IND process, and clinical phase plans for RNL, pipeline expansion through additional drug development candidates, and partnership discussions for RNL, DocePLUS and DoxoPLUS; and future development and/or expansion of its product candidates and therapies in its markets. The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that the Company is not able to successfully develop product candidates that can leverage the FDA’s accelerated regulatory pathways; the early stage of the Company’s product candidates and therapies, the results of its research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s history of losses; the Company’s need for, and ability to raise, additional cash or obtain other sources of funding in the immediate future; the Company’s ability to: (a) obtain and maintain regulatory approvals, (b) continue as a going concern, (c) remain listed on the Nasdaq Capital Market, (d) to obtain or maintain sufficient levels of reimbursement for its tests, and (d) to repay or refinance some or all of its outstanding indebtedness; the outcome of the Company’s partnering/licensing efforts; market and economic conditions; the impact of the COVID-19 pandemic on the Company and the effectiveness of the efforts it has taken or may take in the future in response thereto; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
Westwicke/ICR
(443) 377-4767
Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
Westwicke/ICR
(203) 856-4326
Terri.Clevenger@westwicke.com
FAQ
What is the focus of Plus Therapeutics' ReSPECT™ clinical trial?
When will Plus Therapeutics present its clinical trial data?
Who is leading the presentation at the Society for Neuro-Oncology meeting?
What are the implications of the interim data for recurrent glioblastoma treatment?
What challenges does Plus Therapeutics face in its development process?
